MCID: DDN007
MIFTS: 40

Duodenal Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Duodenal Disease

MalaCards integrated aliases for Duodenal Disease:

Name: Duodenal Disease 12 15
Duodenal Diseases 55 44 73
Duodenum Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4072
MeSH 44 D004378
SNOMED-CT 68 52182008
UMLS 73 C0013289

Summaries for Duodenal Disease

MalaCards based summary : Duodenal Disease, also known as duodenal diseases, is related to zollinger-ellison syndrome and multiple endocrine neoplasia, type i, and has symptoms including constipation and diarrhea. An important gene associated with Duodenal Disease is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are O-linked glycosylation and CLEC7A (Dectin-1) signaling. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include small intestine, lung and ovary, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Wikipedia : 76 The duodenum[help 1] is the first section of the small intestine in most higher vertebrates, including... more...

Related Diseases for Duodenal Disease

Diseases related to Duodenal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 222)
# Related Disease Score Top Affiliating Genes
1 zollinger-ellison syndrome 29.5 MEN1 SCT SST
2 multiple endocrine neoplasia, type i 29.5 MEN1 SCT SST
3 chronic cholangitis 10.3 CDX2 MUC2
4 anus cancer 10.3 CDX2 KRT7
5 chronic cystitis 10.3 CDX2 KRT7
6 rectum adenocarcinoma 10.3 CDX2 KRT7
7 vulva adenocarcinoma 10.3 CDX2 KRT7
8 prostatic acinar adenocarcinoma 10.3 CDX2 KRT7
9 bladder adenocarcinoma 10.3 CDX2 KRT7
10 horseshoe kidney 10.3 CDX2 KRT7
11 cervical adenosquamous carcinoma 10.3 KRT7 MUC6
12 carcinoid tumors, intestinal 10.3 MEN1 SST
13 pancreatic cystadenoma 10.3 MEN1 SST
14 carcinoid syndrome 10.3 MEN1 SST
15 chondroid lipoma 10.3 KRT7 MEN1
16 insulinomatosis and diabetes mellitus 10.3 SCT SST
17 dumping syndrome 10.3 SCT SST
18 angiodysplasia 10.3 SCT SST
19 vipoma 10.3 SCT SST
20 small intestine adenocarcinoma 10.3 MUC2 MUC6
21 cervical polyp 10.3 CDX2 MUC6
22 glucagonoma 10.3 SCT SST
23 ovary neuroendocrine neoplasm 10.3 CDX2 KRT7
24 appendix adenocarcinoma 10.2 CDX2 KRT7
25 mucinous adenofibroma 10.2 CDX2 KRT7
26 anus adenocarcinoma 10.2 CDX2 KRT7
27 eyelid carcinoma 10.2 KRT7 MUC2
28 glandular cystitis 10.2 CDX2 KRT7
29 intestinal neuroendocrine benign tumor 10.2 MEN1 SCT
30 pancreatic somatostatinoma 10.2 MEN1 SST
31 epithelial predominant wilms' tumor 10.2 CDX2 KRT7
32 pancreatic gastrinoma 10.2 MEN1 SCT
33 mucinous intrahepatic cholangiocarcinoma 10.2 CDX2 MUC2 MUC6
34 alveoli adenoma 10.2 KRAS KRT7
35 hernia, hiatus 10.2 ATP12A ATP4A
36 diarrhea 1, secretory chloride, congenital 10.2 ATP12A ATP4A
37 osteopetrosis, autosomal recessive 3 10.2 ATP12A ATP4A
38 myopathy, x-linked, with excessive autophagy 10.2 ATP12A ATP4A
39 paine syndrome 10.2 ATP12A ATP4A
40 esophagitis, eosinophilic, 1 10.2 ATP12A ATP4A
41 aspiration pneumonia 10.2 ATP12A ATP4A
42 anismus 10.2 ATP12A ATP4A
43 microscopic colitis 10.2 ATP12A ATP4A
44 lymphocytic colitis 10.2 ATP12A ATP4A
45 clostridium difficile colitis 10.2 ATP12A ATP4A
46 jejunoileitis 10.2 ATP12A ATP4A
47 esophageal atresia/tracheoesophageal fistula 10.2 ATP12A ATP4A
48 gastric lymphoma 10.2 ATP12A ATP4A
49 blind loop syndrome 10.2 ATP12A ATP4A
50 chronic laryngitis 10.2 ATP12A ATP4A

Graphical network of the top 20 diseases related to Duodenal Disease:



Diseases related to Duodenal Disease

Symptoms & Phenotypes for Duodenal Disease

UMLS symptoms related to Duodenal Disease:


constipation, diarrhea

MGI Mouse Phenotypes related to Duodenal Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 ATP12A ATP4A CDX2 KRAS MEN1 MUC2
2 homeostasis/metabolism MP:0005376 9.61 ATP12A ATP4A CCK CDX2 KRAS KRT7
3 neoplasm MP:0002006 9.02 ATP4A CDX2 KRAS MEN1 MUC2

Drugs & Therapeutics for Duodenal Disease

Drugs for Duodenal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 103577-45-3, 138530-94-6 9578005
2
Lansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 103577-45-3 3883
3
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
4
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 26787-78-0 33613
5
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81103-11-9 84029
6
Trimebutine Approved Phase 4 39133-31-8
7
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 117976-89-3 5029
8
Metronidazole Approved Phase 4,Phase 2,Phase 3,Not Applicable 443-48-1 4173
9
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73590-58-6 4594
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
11
Famotidine Approved Phase 4,Phase 3,Not Applicable 76824-35-6 3325
12
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 51-45-6, 75614-87-8 774
13
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
14
Ticlopidine Approved Phase 4,Phase 2,Not Applicable 55142-85-3 5472
15
Clopidogrel Approved Phase 4,Phase 2,Not Applicable 113665-84-2, 120202-66-6 60606
16
Tetracycline Approved, Vet_approved Phase 4,Not Applicable 60-54-8 5353990
17
Levofloxacin Approved, Investigational Phase 4,Not Applicable 100986-85-4 149096
18
Ofloxacin Approved Phase 4,Not Applicable 82419-36-1 4583
19
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22204-53-1 1302 156391
20
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3 169590-42-5 2662
21
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable
22
Azithromycin Approved Phase 4 83905-01-5 55185 447043
23
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
24
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
25
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
26
Ranitidine Approved Phase 4,Phase 3,Phase 1 66357-35-5, 66357-59-3 3001055
27
Misoprostol Approved Phase 4,Phase 3 59122-46-2 5282381
28
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 77-92-9 311
30
Maleic acid Experimental Phase 4,Phase 1 110-16-7 444266
31
Furazolidone Experimental, Vet_approved Phase 4,Not Applicable 67-45-8 5323714 3435
32 Rebamipide Investigational Phase 4,Phase 3,Phase 2,Not Applicable 90098-04-7
33 Benzimidazole Experimental, Investigational Phase 4 51-17-2
34 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
39 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Not Applicable
40 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
41 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Not Applicable
42 Parasympatholytics Phase 4
43 Autonomic Agents Phase 4,Phase 3,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antiprotozoal Agents Phase 4,Phase 2,Phase 3
46 Antiparasitic Agents Phase 4,Phase 2,Phase 3
47 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 340)
# Name Status NCT ID Phase Drugs
1 Oral vs Intravenous and Proton Pump Inhibitor (PPI)for Peptic Ulcer Bleeding (PUB) Unknown status NCT01123031 Phase 4 lansoprazole;esomeprazole
2 Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer Unknown status NCT00471029 Phase 4 esomeprazole
3 Helicobacter Pylori Empiric Treatment in Ulcer Bleeding Unknown status NCT00687336 Phase 4
4 H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection Unknown status NCT00926809 Phase 4 Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin;Lansoprazole (proton pump inhibitor), placebo
5 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
6 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
7 Concomitant Therapy of H. Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
8 The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients Completed NCT02648659 Phase 4 Ilaprazole;Amoxicillin;Clarithromycin;Metronidazole
9 Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot Completed NCT02536989 Phase 4 omeprazole;omeprazole
10 Fast-track Surgery for Perforated Peptic Ulcers Completed NCT01620671 Phase 4
11 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers Completed NCT01353144 Phase 4 aspirin
12 Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion Completed NCT00843063 Phase 4 pantoprazole vs famotidine
13 The Dissemination of Consensus Recommendations on Upper Gastrointestinal Bleeding Completed NCT00840008 Phase 4
14 Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers Completed NCT00778193 Phase 4 Naproxen;Aspirin;Celecoxib;Clopidogrel;Placebo
15 Ulcer Prevention Study in Post Gastric Bypass Patients Completed NCT00557349 Phase 4 Omeprazole;Famotidine
16 Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment Completed NCT00534443 Phase 4
17 Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population Completed NCT00137033 Phase 4 Celecoxib;Naproxen;ASA
18 Argon Plasma Coagulation for Bleeding Peptic Ulcers Completed NCT02241044 Phase 4
19 The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia Completed NCT01822600 Phase 4 Human albumin;Omeprazole
20 The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers Completed NCT01591083 Phase 4 esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
21 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
22 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
23 Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy Completed NCT00164866 Phase 4 Omeprazole
24 Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
25 Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding Completed NCT00731601 Phase 4 pantoprazole;pantoprazole
26 Empirical Rescue Therapies of Helicobacter Pylori Infection Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
27 Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
28 Aizthromycin or Clarithromycin in H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
29 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate
30 Clarithromycin Resistant Tailored Therapy Completed NCT01453036 Phase 4
31 Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers Completed NCT00279123 Phase 4 pantoprazole infusion;pantoprazole bolus;no treatment
32 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
33 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
34 Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy Completed NCT00272467 Phase 4 Rebamipide;Omeprazole
35 Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer Completed NCT00239551 Phase 4 Prevacid
36 Post-Marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer Completed NCT00233389 Phase 4 Rebamipide
37 A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium Completed NCT00125736 Phase 4 E0671;rabeprazole sodium;E0671 placebo
38 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
39 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
40 An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium Completed NCT00428701 Phase 4 Esomeprazole Sodium
41 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
42 Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer Completed NCT01190657 Phase 4 Selbex;Selbex
43 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
44 Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
45 NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
46 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
47 Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer Recruiting NCT03675672 Phase 4 Misoprostol Oral Tablet;Placebo Oral Tablet
48 Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Recruiting NCT02175186 Phase 4 ALBIS;Placebo
49 Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients Recruiting NCT02456012 Phase 4 oral esomeprazole 20 mg twice daily;oral esomeprazole 20 mg once daily
50 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers Recruiting NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets

Search NIH Clinical Center for Duodenal Disease

Cochrane evidence based reviews: duodenal diseases

Genetic Tests for Duodenal Disease

Anatomical Context for Duodenal Disease

MalaCards organs/tissues related to Duodenal Disease:

41
Small Intestine, Lung, Ovary, Pituitary, Pancreas, Thymus, Appendix

Publications for Duodenal Disease

Articles related to Duodenal Disease:

(show all 24)
# Title Authors Year
1
Imaging of non-neoplastic duodenal diseases. A pictorial review with emphasis on MDCT. ( 29388052 )
2018
2
Factors associated with gastro-duodenal disease in patients undergoing upper GI endoscopy at the Korle-Bu Teaching Hospital, Accra, Ghana. ( 27605979 )
2016
3
A Case of Acute Esophageal Necrosis and Duodenal Disease in a Patient With Adrenal Insufficiency. ( 27392758 )
2016
4
Imaging spectrum of nonneoplastic duodenal diseases. ( 27572283 )
2016
5
To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. ( 25780285 )
2015
6
Diarrhoea and duodenal disease. Coeliac disease. ( 25107558 )
2014
7
Helicobacter pylori genetic diversity and gastro-duodenal diseases in Malaysia. ( 25503415 )
2014
8
Association of genetic polymorphisms in IL17A and IL17F with gastro-duodenal diseases. ( 23012664 )
2012
9
Advanced duodenal disease in familial adenomatous polyposis: how frequently should patients be followed up after successful therapy? ( 22760847 )
2012
10
Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. ( 17934843 )
2008
11
A simple multiplex PCR assay for diagnosing virulent Helicobacter pylori infection in human gastric biopsy specimens from subjects with gastric carcinoma and other gastro-duodenal diseases. ( 17850305 )
2007
12
The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. ( 18039108 )
2006
13
Pylorus-preserving pancreaticoduodenectomy for advanced duodenal disease in familial adenomatous polyposis (Br J Surg 2004; 91: 1157-1164). ( 15685693 )
2005
14
Pylorus-preserving pancreaticoduodenectomy for advanced duodenal disease in familial adenomatous polyposis. ( 15449267 )
2004
15
Correlation between erosive oesophageal and gastro-duodenal diseases. the influence of aspirin, simple analgesics, and Helicobacter pylori. ( 12468951 )
2002
16
Helicobacter pylori infection and subsequent peptic duodenal disease among young adults. ( 10869336 )
2000
17
Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. ( 9681848 )
1998
18
Prevalence of Campylobacter pylori in esophagitis, gastritis, and duodenal disease. ( 2730254 )
1989
19
Possible pathogenetic pathways of Campylobacter pylori in gastro-duodenal disease. ( 3166532 )
1988
20
A radiological review of duodenal disease. ( 5314954 )
1971
21
SWEAT ELECTROLYTES IN PATIENTS WITH GASTRO-DUODENAL DISEASE. ( 14178713 )
1964
22
ABO blood groups and gastro-duodenal diseases. ( 13355800 )
1956
23
Why the infrequency of malignant duodenal disease? ( 13011426 )
1952
24
The Radiological Factor in the Diagnosis of Gastric and Duodenal Disease. ( 30438541 )
1929

Variations for Duodenal Disease

Expression for Duodenal Disease

Search GEO for disease gene expression data for Duodenal Disease.

Pathways for Duodenal Disease

GO Terms for Duodenal Disease

Cellular components related to Duodenal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Duodenal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 digestion GO:0007586 9.46 CCK SST
2 ATP hydrolysis coupled proton transport GO:0015991 9.43 ATP12A ATP4A
3 cellular sodium ion homeostasis GO:0006883 9.4 ATP12A ATP4A
4 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.37 ATP12A ATP4A
5 maintenance of gastrointestinal epithelium GO:0030277 9.32 MUC2 MUC6
6 cellular potassium ion homeostasis GO:0030007 9.26 ATP12A ATP4A
7 sodium ion export across plasma membrane GO:0036376 9.16 ATP12A ATP4A
8 O-glycan processing GO:0016266 9.13 MUC1 MUC2 MUC6
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.92 KRAS MUC1 MUC2 MUC6

Molecular functions related to Duodenal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.33 CCK SCT SST
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
3 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Duodenal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....